Pharmaceutical Technology
June 02, 2010
Issue PDF
34
6
Excipients Step into the Spotlight
June 02, 2010
From The Editor
34
6
The birth of "the pill" and harmonization created a new paradigm for global standards.
June 02, 2010
Ingredients Insider
34
6
CROs and CMOs adapt their business models and capabilities to meet sponsor companies' need to reduce costs and accelerate development time.
June 02, 2010
Viewpoint
34
6
The author suggests industry may need a NATO-type organization to even out inspections.
June 02, 2010
Special Report
34
6
Industry and regulatory experts discuss excipient testing, regulatory expectations, supply-chain challenges, and pricing in this Speakers Roundtable. This article contains bonus online material and podcasts.
June 02, 2010
Outsourcing Outlook
34
6
The sovereign debt crisis in the EU could greatly change the landscape for contract services.
June 02, 2010
Online Exclusives
34
6
Puerto Rico, long a mainstay of solid-dosage manufacturing, intensifies efforts in biopharmaceutical manufacturing and research and development.
June 02, 2010
Packaging Forum
34
6
Interphex attendees found packaging machines and containers with increased functionality. This article contains online bonus material.
June 02, 2010
Washington Report
34
6
FDA and industry seek to ensure drug quality and safety in a world complicated by global outsourcing and rising theft.
June 02, 2010
Industry Leaders: Q&A
34
6
The president of Binder, a manufacturer of simulation chambers, addresses the consolidation of Big Pharma, and more.
June 02, 2010
PharmTech Talk
34
6
A PharmTech forum to discuss the industry's efforts in corporate social responsibility and sustainability.
June 02, 2010
Inside USP
34
6
USP membership meeting prepared the standards-setting body to meet modern challenges.
June 02, 2010
In the Spotlight
34
6
Editors' picks of pharmaceutical science and technology innovations.
June 02, 2010
Online Exclusives
34
6
A timely new book explains techniques for conformational analysis.
June 02, 2010
News
34
6
Europe moves to place excipient GMP and GDP standards on the same level as active pharmaceutical ingredients.
June 02, 2010
Agent-in Place
34
6
Too much or too little control can actually lead to the same result.
June 02, 2010
Peer-Reviewed
34
6
The authors recommend a strategy for classifying similar nonstainless-steel surfaces into three groups based upon the analytical recovery that was observed in this study.